3.74
price up icon3.17%   0.115
after-market 시간 외 거래: 3.64 -0.10 -2.67%
loading
전일 마감가:
$3.625
열려 있는:
$3.65
하루 거래량:
286.95K
Relative Volume:
0.73
시가총액:
$275.57M
수익:
$351.37M
순이익/손실:
$-174.01M
주가수익비율:
-1.8068
EPS:
-2.07
순현금흐름:
$-126.94M
1주 성능:
+5.95%
1개월 성능:
+16.15%
6개월 성능:
+6.25%
1년 성능:
+14.02%
1일 변동 폭
Value
$3.65
$3.7599
1주일 범위
Value
$3.425
$3.80
52주 변동 폭
Value
$2.455
$4.145

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Name
명칭
Atea Pharmaceuticals Inc
Name
전화
857-204-8109
Name
주소
225 FRANKLIN STREET, BOSTON
Name
직원
56
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
AVIR's Discussions on Twitter

AVIR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
AVIR
Atea Pharmaceuticals Inc
3.74 275.57M 351.37M -174.01M -126.94M -2.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-08-13 업그레이드 Morgan Stanley Underweight → Equal-Weight
2023-08-10 다운그레이드 JP Morgan Neutral → Underweight
2022-01-06 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2021-11-18 다운그레이드 SVB Leerink Outperform → Mkt Perform
2021-10-20 다운그레이드 JP Morgan Overweight → Neutral
2021-10-05 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-11-25 개시 Evercore ISI Outperform
2020-11-24 개시 JP Morgan Overweight
2020-11-24 개시 Morgan Stanley Overweight
2020-11-24 개시 William Blair Outperform
모두보기

Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스

pulisher
Jun 17, 2025

Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance

Jun 17, 2025
pulisher
Jun 15, 2025

Bank of America Corp DE Boosts Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Millennium Management LLC Invests $75,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 14, 2025
pulisher
Jun 09, 2025

Squarepoint Ops LLC Buys 35,053 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Two Sigma Investments LP - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Jane Street Group LLC Decreases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Public Employees Retirement System of Ohio Trims Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Sells 11,900 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Buys 6,163 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace

Jun 02, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 27, 2025
pulisher
May 26, 2025

Northern Trust Corp Boosts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 26, 2025
pulisher
May 24, 2025

D. E. Shaw & Co. Inc. Purchases 62,505 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 24, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades Atea Pharmaceuticals (NASDAQ:AVIR) to “Hold” - Defense World

May 24, 2025
pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Purchases 3,882 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 17, 2025
pulisher
May 16, 2025

Q2 EPS Forecast for Atea Pharmaceuticals Reduced by Analyst - Defense World

May 16, 2025
pulisher
May 14, 2025

Dimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 14, 2025
pulisher
May 14, 2025

Transcript : Atea Pharmaceuticals, Inc.Special Call - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Atea Pharmaceuticals Advances HCV Treatment Trials - TipRanks

May 14, 2025
pulisher
May 12, 2025

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 12, 2025
pulisher
May 10, 2025

Wells Fargo & Company MN Increases Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 10, 2025
pulisher
May 10, 2025

Atea Pharmaceuticals (AVIR) to Release Earnings on Monday - Defense World

May 10, 2025
pulisher
May 08, 2025

Atea reports high efficacy in Phase 2 HCV drug trial By Investing.com - Investing.com Nigeria

May 08, 2025
pulisher
May 08, 2025

Barclays PLC Increases Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

May 08, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals (AVIR) Reveals Promising Phase 2 Results for Hepatitis C Treatment | AVIR Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Atea reports high efficacy in Phase 2 HCV drug trial - Investing.com

May 07, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals Announces Full Results from Phase 2 - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals Announces Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus (HCV) Presented At EASL Congress 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - Stock Titan

May 07, 2025
pulisher
May 01, 2025

A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Atea Pharmaceuticals (AVIR) Organizes HCV Treatment Panel & Announces Q1 Results | AVIR Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times

May 01, 2025
pulisher
Apr 26, 2025

JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX

Apr 25, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News

Apr 22, 2025
pulisher
Apr 18, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire

Apr 17, 2025

Atea Pharmaceuticals Inc (AVIR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Atea Pharmaceuticals Inc 주식 (AVIR) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
BERGER FRANKLIN M
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
506,497
Duncan Barbara Gayle
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
62,750
Polsky Bruce
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
95,206
Adams Jerome M.
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
62,750
Lucidi Bruno
Director
Jun 20 '25
Option Exercise
0.00
29,600
0
112,750
BERGER FRANKLIN M
Director
Dec 10 '24
Sale
2.85
359,606
1,023,475
451,897
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
자본화:     |  볼륨(24시간):